Leukocyte nadir as a predictive factor for efficacy of adjuvant chemotherapy in breast cancer. Results from the prospective trial SBG 2000-1

Autor: Asgerdur Sverrisdottir, Kenneth Villman, Johan Ahlgren, Henrik Lindman, Carl Blomqvist, Jonas Bergh, Paula Poikonen-Saksela, Per Edlund, Søren Cold, Martin Andersson, Lars Stenbygaard, Troels Bechmann, Bent Ejlertsen, Lena Tennvall Nittby

Publikováno v: Poikonen-Saksela, P, Lindman, H, Sverrisdottir, A, Edlund, P, Villman, K, Tennvall Nittby, L, Cold, S, Bechmann, T, Stenbygaard, L, Ejlertsen, B, Andersson, M, Blomqvist, C, Bergh, J & Ahlgren, J 2020, ' Leukocyte nadir as a predictive factor for efficacy of adjuvant chemotherapy in breast cancer. Results from the prospective trial SBG 2000-1 ', Acta Oncologica, vol. 59, no. 7, pp. 825-832 . https://doi.org/10.1080/0284186X.2020.1757149
Poikonen-Saksela, P, Lindman, H, Sverrisdottir, A, Edlund, P, Villman, K, Tennvall Nittby, L, Cold, S, Bechmann, T, Stenbygaard, L, Ejlertsen, B, Andersson, M, Blomqvist, C, Bergh, J & Ahlgren, J 2020, ' Leukocyte nadir as a predictive factor for efficacy of adjuvant chemotherapy in breast cancer. Results from the prospective trial SBG 2000–1 ', Acta Oncologica, vol. 59, no. 7, pp. 825-832 . https://doi.org/10.1080/0284186X.2020.1757149

Background: Retrospective studies have suggested that chemotherapy-induced leukopenia is associated with improved recurrence-free or overall survival. The SBG 2000–1 trial was designed to verify the favorable prognosis associated with chemotherapy-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::894f834caf497ceaa864d4c9c0e130f4
https://vbn.aau.dk/da/publications/d409389a-005e-4a1a-b899-33280889fc9c

A population-based study on the first forty-eight breast cancer patients receiving trastuzumab (Herceptin) on a named patient basis in Sweden

Autor: Asgerdur Sverrisdottir, Jenny Andersson, Barbro Linderholm, Sigrid Klaar, Martin Söderberg, Birgitta Lindh, Jan Tennvall, Gudrun Greim, Dagny Pettersson-Sköld, Jonas Bergh, Henrik Lindman, Lena Tennvall-Nittby

Publikováno v: Karolinska Institutet

Several studies have presented data on the efficacy and tolerability of trastuzumab within clinical trials. As a minority of patients is included in these trials, we undertook this retrospective study to describe trastuzumab therapy in clinical routi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a7ffe994c622371280c1f57c4c2b29f
https://pubmed.ncbi.nlm.nih.gov/12195747

The total incidence of loco-regional recurrence in a randomized trial of breast cancer TNM stage II. The South Sweden Breast Cancer Trial

Autor: T. Landberg, Ingrid Tengrup, Lena Tennvall-Nittby

Publikováno v: Acta oncologica (Stockholm, Sweden). 32(6)

We studied loco-regional recurrence during follow-up (median observation time 8 years) in 1,153 patients, who underwent modified mastectomy and were randomly assigned to one of the following postoperative treatments; Premenopausal patients: radiother

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::522e8c969257088ff22d00cf559580c5
https://pubmed.ncbi.nlm.nih.gov/8260183